Can you Diagnose Immune Thrombocytopenia in Myeloma? A Case of Thrombocytopenia in a Patient with Multiple Myeloma.

Eur J Case Rep Intern Med

Department of Internal Medicine, Unidade Local de Saúde da Região de Leiria, Leiria, Portugal.

Published: November 2024

Unlabelled: Multiple myeloma (MM) is the second most common haematological malignancy, the diagnosis of which has doubled in recent years. Immune thrombocytopenia consists of isolated thrombocytopenia secondary to antibody mediated peripheral platelet destruction. In most cases, there is no identifiable cause (primary immune thrombocytopenia). Its association with multiple myeloma is rare. Early recognition of this association is essential for raising awareness among clinicians, allowing for a rapid differential diagnosis and therapeutic optimization, reducing side effects and improving prognosis. Thus, we present a clinical case of concomitant immune thrombocytopenia and MM, whose initial presentation was thrombocytopenia. This clinical case is the first case among thirteen described in the literature in which chemotherapy was the initial treatment for both pathologies, as seen in this review.

Learning Points: Multiple myeloma is the second most common haematological malignancy and is associated with a broad group of pathologies, including, in some cases, autoimmune manifestations. Thrombocytopenia in multiple myeloma is common due to therapy or bone marrow plasmacytosis, but the association of immune thrombocytopenia with multiple myeloma is rare.Raising clinicians' awareness of the association of multiple myeloma with immune thrombocytopenia is essential for a rapid differential diagnosis. This can alter therapeutic possibilities and consequent patient prognoses.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11623356PMC
http://dx.doi.org/10.12890/2024_004981DOI Listing

Publication Analysis

Top Keywords

multiple myeloma
28
immune thrombocytopenia
24
thrombocytopenia
10
myeloma second
8
second common
8
common haematological
8
haematological malignancy
8
association multiple
8
rapid differential
8
differential diagnosis
8

Similar Publications

Antisense oligonucleotides-based approaches for the treatment of multiple myeloma.

Int J Biol Macromol

December 2024

Faculty of Medical Engineering, National University of Science and Technology Politehnica Bucharest, Gheorghe Polizu 1-7, 011061 Bucharest, Romania; Advanced Polymer Materials Group, University Politehnica of Bucharest, Gheorghe Polizu 1-7, 011061 Bucharest, Romania; ebio-Hub Research Centre, University Politehnica of Bucharest-Campus, Iuliu Maniu 6, 061344 Bucharest, Romania. Electronic address:

Multiple myeloma (MM), a hematological malignancy which affects the monoclonal plasma cells in the bone marrow, is in rising incidence around the world, accounting for approximately 2 % of newly diagnosed cancer cases in the US, Australia, and Western Europe. Despite the progress made in the last few years in the available therapeutic options (e.g.

View Article and Find Full Text PDF

Genetic architecture of Multiple Myeloma and its prognostic implications - An updated review.

Malays J Pathol

December 2024

Universiti Sains Malaysia, School of Medical Sciences, Human Genome Centre, Health Campus, Kelantan, Malaysia.

Multiple myeloma (MM), a clonal B-cell neoplasia, is an incurable and heterogeneous disease where survival ranges from a few months to more than 10 years. The clinical heterogeneity of MM arises from multiple genomic events that result in tumour development and progression. Recurring genomic abnormalities including cytogenetic abnormalities, gene mutations and abnormal gene expression profiles in myeloma cells have a strong prognostic power.

View Article and Find Full Text PDF

Due to its course, multiple myeloma may negatively affect the functioning of patients. Different treatment methods are also associated with patients' varying perception of their health condition. The purpose of this study is to determine the disease-specific complaints among multiple myeloma patients during selected treatment methods-chemotherapy, autologous hematopoietic stem cell transplantation, and supportive therapy.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!